GlassScriptPhysician profile
Kelley Ann Dotson
NPI 1326686684
$7,687.14
in general payments reported to CMS, 2019-2025
19 companies · $2,890 in 2025
The $2,890 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.20 · 2023: $1,027 · 2024: $3,720 · 2025: $2,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,068 · Education: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,068.06 |
| Education | $568.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,916.53 | 2022-2025 | Tremfya |
| Abbvie INC. | $1,293.88 | 2023-2025 | |
| Ucb, INC. | $714.10 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $517.16 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $474.57 | 2023-2025 | |
| Amgen INC. | $397.68 | 2023-2025 | Otezla |
| Lilly USA, LLC | $307.44 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $288.36 | 2023-2024 | Vtama |
| Genzyme Corporation | $265.23 | 2023-2025 | |
| Galderma Laboratories, L.P. | $250.63 | 2024-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $247.81 | 2023-2024 | Dupixent |
| Pfizer INC. | $205.01 | 2024-2025 | |
| Incyte Corporation | $188.19 | 2024-2025 | Opzelura |
| Hill Dermaceuticals, INC. | $165.32 | 2024 | Tolak |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.73 | 2024 | Spevigo, Cyltezo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $111.23 | 2022-2024 | Ilumya |
| Arcutis Biotherapeutics, INC. | $96.09 | 2025 | Zoryve |
| Organon LLC | $94.34 | 2025 | Vtama |
| Biofrontera INC. | $41.84 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Dotson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.